Methamphetamine-Induced Dopamine Transporter Complex Formation and Dopaminergic Deficits: The Role of D2 Receptor Activation
Authors:
- Pei-Wen ChuPCPei-Wen Chu
- Elliot T. WaltersEWElliot T. Walters
- Glen R. HansonGHGlen R. Hanson
- Annette E. FleckensteinAFAnnette E. Fleckenstein
- 1 October 2010
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 335 (1) , 207-212
Abstract
Methamphetamine (METH) abuse is a serious public health issue. Of particular concern are findings that repeated high-dose administrations of METH cause persistent dopaminergic deficits in rodents, nonhuman primates, and humans. Previous studies have also revealed that METH treatment causes alterations in the dopamine transporter (DAT), including the formation of higher molecular mass DAT-associated complexes. The current study extends these findings by examining mechanisms underlying DAT complex formation. The association among DAT complex formation and other METH-induced phenomena, including alterations in vesicular monoamine transporter 2 (VMAT2) immunoreactivity, astrocytic activation [as assessed by increased glial fibrillary acidic protein (GFAP) immunoreactivity], and persistent dopaminergic deficits was also explored. Results revealed that METH-induced DAT complex formation and reductions in VMAT2 immunoreactivity precede increases in GFAP immunoreactivity. Furthermore, and as reported previously for DAT complexes, pretreatment with the D2 receptor antagonist eticlopride [S-(−)-3-chloro-5-ethyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-hydroxy-2-methoxybenzamide hydrochloride] attenuated the decrease in VMAT2 immunoreactivity as assessed 24 h after METH treatment. DAT complexes distinct from those present 24 h after METH treatment, decreases in VMAT2 immunoreactivity, and increased GFAP immunoreactivity were present 48 to 72 h after METH treatment. Pretreatment with eticlopride attenuated each of these phenomena. Finally, DAT complexes were present 7 days after METH treatment, a time point at which VMAT2 and DAT monomer immunoreactivity were also reduced. Eticlopride pretreatment attenuated each of these phenomena. These findings provide novel insight into not only receptor-mediated mechanisms underlying the effects of METH but also the interaction among factors that probably are associated with the persistent dopaminergic deficits caused by the stimulant.Keywords
This publication has 36 references indexed in Scilit:
- Methamphetamine toxicity and messengers of deathBrain Research Reviews, 2009
- Mechanisms Underlying Methamphetamine-Induced Dopamine Transporter Complex FormationThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disordersJournal of Neurochemistry, 2009
- Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: Neurotoxic and therapeutic implicationsNeuropharmacology, 2009
- PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicityNeuropeptides, 2008
- Differential regional effects of methamphetamine on dopamine transportEuropean Journal of Pharmacology, 2008
- The newly synthesized pool of dopamine determines the severity of methamphetamine‐induced neurotoxicityJournal of Neurochemistry, 2007
- A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamineJournal of Neurochemistry, 2007
- Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicityExperimental Neurology, 2004
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976